News FDA blocks trials that send US cells to 'hostile' countries The FDA says it will review clinical trials that send US citizens' cells to 'hostile countries' as the agency's leadership in this area is sidelined.
R&D Advances in manufacturing in vivo lentiviral vectors: Challe... Lentiviral vectors (LVVs) have proven to be extremely versatile genetic delivery vehicles, gaining space as a gene transfer technology tool used both for cell and gene therapies.
R&D Sponsored Exploring the future: Opportunities and challenges in cell a... Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.
News Bayer gains ground in two-fronted Parkinson's offensive Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.
News Amid BIOSECURE Act speculation, WuXi AppTec sells unit WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum
News Mesoblast finally pushes GvHD cell therapy over finish line At its third attempt, Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children.
News ACIP backs block on flu vaccines with thimerosal additive The new CDC vaccines committee has voted against the use of thimerosal, a preservative that anti-vaccine activists have linked to autism.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face